Agios Pharmaceuticals, Inc. (0HB0.L)
USD 41.74
(-0.05%)
USD 41.74
(-0.05%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 56.98 Million USD | -20.85% |
| 2022 | 71.99 Million USD | -16.22% |
| 2021 | 85.93 Million USD | -12.12% |
| 2020 | 97.78 Million USD | -8.39% |
| 2019 | 106.74 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 48.76 Million USD | -7.9% |
| 2024 Q3 | - USD | -100.0% |
| 2024 Q1 | 52.94 Million USD | -7.1% |
| 2023 Q3 | 60.83 Million USD | -5.86% |
| 2023 FY | 56.98 Million USD | -20.85% |
| 2023 Q4 | 56.98 Million USD | -6.32% |
| 2023 Q1 | 68.34 Million USD | -5.07% |
| 2023 Q2 | 64.62 Million USD | -5.45% |
| 2022 Q3 | 76.55 Million USD | -4.31% |
| 2022 Q2 | 80 Million USD | -3.16% |
| 2022 Q1 | 82.61 Million USD | -3.86% |
| 2022 FY | 71.99 Million USD | -16.22% |
| 2022 Q4 | 71.99 Million USD | -5.95% |
| 2021 Q2 | 92.13 Million USD | -3.32% |
| 2021 Q4 | 85.93 Million USD | -3.27% |
| 2021 Q3 | 88.84 Million USD | -3.58% |
| 2021 FY | 85.93 Million USD | -12.12% |
| 2021 Q1 | 95.3 Million USD | -2.55% |
| 2020 Q3 | 358.22 Million USD | 1.39% |
| 2020 FY | 97.78 Million USD | -8.39% |
| 2020 Q4 | 97.78 Million USD | -72.7% |
| 2020 Q1 | 104.58 Million USD | -2.03% |
| 2020 Q2 | 353.32 Million USD | 237.85% |
| 2019 Q2 | 110.07 Million USD | 66.76% |
| 2019 FY | 106.74 Million USD | 0.0% |
| 2019 Q4 | 106.74 Million USD | -1.25% |
| 2019 Q3 | 108.09 Million USD | -1.8% |
| 2019 Q1 | 66 Million USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | -133.826% |
| Dynavax Technologies Corporation | 252.41 Million USD | 77.423% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -71.671% |
| Perrigo Company plc | 3.63 Billion USD | 98.431% |
| Illumina, Inc. | 1.48 Billion USD | 96.173% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.818% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -5598.8% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 99.292% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.56% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 67.202% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 97.892% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -142.1% |
| Waters Corporation | 2.3 Billion USD | 97.528% |
| Biogen Inc. | 7.18 Billion USD | 99.207% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -70.037% |
| Evolus, Inc. | 120.35 Million USD | 52.652% |
| Adicet Bio, Inc. | 17.7 Million USD | -221.912% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -53.693% |
| bluebird bio, Inc. | 224.41 Million USD | 74.606% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 88.638% |
| FibroGen, Inc. | 89.69 Million USD | 36.466% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 97.916% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -1659.632% |
| Homology Medicines, Inc. | 43.17 Million USD | -31.99% |
| Geron Corporation | 35.05 Million USD | -62.586% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 97.568% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 85.307% |
| Myriad Genetics, Inc. | 130.9 Million USD | 56.464% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -5988.462% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 41.096% |
| Zoetis Inc. | 6.56 Billion USD | 99.132% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -1194.593% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 97.115% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 90.391% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 92.136% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -66.68% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 95.931% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -24.719% |
| Verastem, Inc. | 40.08 Million USD | -42.164% |
| Nektar Therapeutics | 112.62 Million USD | 49.4% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 67.997% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -1753.871% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 94.968% |
| OPKO Health, Inc. | 222.03 Million USD | 74.334% |
| Exelixis, Inc. | 189.94 Million USD | 69.997% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 77.937% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | 56.185% |
| Imunon, Inc. | 1.13 Million USD | -4902.05% |
| Blueprint Medicines Corporation | 610.96 Million USD | 90.672% |
| Insmed Incorporated | 1.19 Billion USD | 95.225% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 96.199% |
| TG Therapeutics, Inc. | 100.11 Million USD | 43.079% |
| Incyte Corporation | 29.16 Million USD | -95.419% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 87.237% |